S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 83 200 KRW -2.92% Market Closed
Market Cap: 1.7T KRW
Have any thoughts about
ST Pharm Co Ltd?
Write Note

ST Pharm Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ST Pharm Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
S
ST Pharm Co Ltd
KOSDAQ:237690
Interest Income Expense
â‚©11.5B
CAGR 3-Years
N/A
CAGR 5-Years
26%
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Interest Income Expense
â‚©48.6B
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Interest Income Expense
â‚©959.6m
CAGR 3-Years
-26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Interest Income Expense
â‚©860.4m
CAGR 3-Years
N/A
CAGR 5-Years
-15%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Interest Income Expense
â‚©28B
CAGR 3-Years
12%
CAGR 5-Years
71%
CAGR 10-Years
53%
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Interest Income Expense
-â‚©4.7B
CAGR 3-Years
-53%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

ST Pharm Co Ltd
Glance View

Market Cap
1.6T KRW
Industry
Life Sciences Tools & Services

ST Pharm Co., Ltd. develops and manufactures pharmaceutical products. The company is headquartered in Siheung, Gyeonggi-Do. The company went IPO on 2016-06-23. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The firm's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
97 768.06 KRW
Undervaluation 15%
Intrinsic Value
Price
S

See Also

What is ST Pharm Co Ltd's Interest Income Expense?
Interest Income Expense
11.5B KRW

Based on the financial report for Sep 30, 2024, ST Pharm Co Ltd's Interest Income Expense amounts to 11.5B KRW.

What is ST Pharm Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
26%

Back to Top